Roughly 40 to 50 percent of hypertrophic cardiomyopathy cases show no clear familial inheritance pattern. Roughly 40 to 60 percent of people with HCM carry a pathogenic variant in a sarcomere gene, the set of genes that encode the heart’s contractile proteins, which leaves about half of patients with no identifiable mutation on current panels.
The remaining cases include de novo mutations that arise spontaneously, genotype-negative familial clusters that science cannot yet explain, and non-genetic conditions that mimic HCM on imaging.
The piece below covers the genetics, the look-alike conditions, and the practical steps for newly diagnosed patients and the families around them. It is written for adults who want a clear-eyed view of how each workup decision shapes the next one.
Hypertrophic Cardiomyopathy Starts With a Thickened Heart Muscle
A diagnosis of HCM begins on an imaging table, not in a genetics lab. Cardiologists measure the wall of the left ventricle (the heart’s main pumping chamber) and look for thickening of 15 millimeters or more that cannot be explained by high blood pressure, valve disease, or intense athletic training alone. Echocardiography (an ultrasound of the heart) is the standard first test, and cardiac MRI often follows to confirm the pattern and rule out scarring.
The distinction that matters most is between primary HCM and secondary forms. Primary, or sarcomeric, HCM arises from a problem in the contractile proteins of the heart muscle itself. Secondary hypertrophy looks identical on a scan but comes from another disease: an infiltrative disorder, a storage disease, or chronic pressure overload. Labeling someone with “HCM” before excluding those mimics is one of the most common errors in cardiology workups, and avoiding it protects you from years of misdirected treatment.
Family context shapes your next decision. A clinician who sees unexplained left ventricular hypertrophy in someone under 50 will ask about sudden cardiac death in relatives, unexplained fainting, and prior diagnoses of an “enlarged heart.” When that history lights up, genetic testing becomes a strong next step. When the history is silent, the workup still has to rule out phenocopies (non-genetic conditions that mimic HCM) before anyone assumes the cause is genetic at all.
Most HCM Traces Back to Sarcomere Gene Mutations
Autosomal Dominant Inheritance in Plain Language
Most inherited HCM follows an autosomal dominant pattern, meaning a single copy of the altered gene from one parent is enough to raise risk. Each child of an affected parent has a 50 percent chance of inheriting the variant, regardless of sex. That is why a disease can show up in a child even when the parent looks perfectly healthy on a scan.
Penetrance (the likelihood that someone carrying the variant will ever show signs of disease) is incomplete in HCM, so a carrier can live a full life without obvious thickening. Expressivity varies too: one relative might have a mildly thickened wall, while another with the same variant develops severe obstruction or arrhythmias.
The genetic dice roll is real, and the same mutation does not produce the same disease in every body, which is why your own clinical course can diverge sharply from a relative’s.
The Two Genes Behind Most Genotype-Positive Cases
Two genes account for the majority of identifiable genetic HCM: MYBPC3 (cardiac myosin-binding protein C) and MYH7 (beta-myosin heavy chain). Together, they explain roughly 70 to 80 percent of genotype-positive cases. More than 1,500 mutations across 11 or more sarcomere genes have been catalogued so far, and the list keeps growing as ClinGen, an NIH-funded resource that curates clinical relevance of genomic variants, refines which variants truly cause disease.
Knowing the specific gene and variant matters for your family screening, prognosis, and sometimes for eligibility in gene-targeted clinical trials. The variant is also the cleanest way to test your relatives, since imaging alone can miss early or mild disease.
A Substantial Share of HCM Patients Test Negative for Known Mutations
Current gene panels do not catch every case. Up to half of people with a clinical HCM diagnosis have no detectable pathogenic sarcomere variant with the technology available today. That gap can mean several things, and it does not automatically mean the disease is not genetic. Understanding why matters for how you plan the next round of screening.
De Novo Mutations and the “No Family History” Scenario
Some patients carry a de novo mutation, a brand-new genetic change that occurred during sperm or egg formation, or very early in embryonic development. Neither parent carries the variant, so your family history is clean. A 2024 review in a major cardiology journal noted that de novo variants are increasingly recognized in HCM, especially in pediatric and severe presentations.
You may be the first case in the family, the risk to siblings is low, and the risk to your own children is the standard 50 percent.
Why Genotype-Negative Patients Still Need Family Screening
A negative panel reflects current knowledge, not a biological guarantee. The cause could be a mutation in a gene not yet on the panel, a structural variant that sequencing misses, or an epigenetic factor (a chemical change that alters how a gene is expressed, without changing the DNA letters themselves) that no current test can read.
The American Heart Association and the European Society of Cardiology both recommend clinical screening with imaging for first-degree relatives of all HCM patients, including those who test negative, because unexplained familial clustering still shows up in real-world cohorts and no one can afford to wait for the science to catch up.
Those unexplained clusters drive clinicians to look beyond sarcomere genes for an answer.
Several Non-Genetic Conditions Can Masquerade as HCM
Before any HCM diagnosis is locked in, a competent workup has to rule out conditions that produce the same wall thickening for entirely different reasons. These are called phenocopies, and missing them can delay proper management for years. Your cardiologist’s job at this stage is to prove the thickening is primary, not to assume it.
| Condition | What It Is | Key Clue That Separates It From Sarcomeric HCM |
|---|---|---|
| Cardiac amyloidosis | Protein deposits (most often transthyretin) infiltrate the heart wall | Low voltage on ECG despite thick walls; characteristic findings on cardiac MRI and bone scan |
| Fabry disease | Missing enzyme leads to glycolipid buildup in the heart, kidneys, and nerves | Reduced alpha-galactosidase A activity; often features such as kidney problems, burning limb pain, or angiokeratomas (small dark red skin lesions) |
| Danon disease | Lysosomal storage disorder caused by LAMP2 variants | Severe hypertrophy in adolescents, often with pre-excitation on ECG and skeletal muscle weakness |
| PRKAG2 syndrome | Glycogen storage disease affecting cardiac conduction | Hypertrophy with short PR interval or pre-excitation on ECG; risk of progressive conduction disease |
| Athlete’s heart | Physiological adaptation to sustained endurance or strength training | Remodels (shrinks) with 3 to 6 months of deconditioning; cavity size often enlarges alongside the wall |
The athlete’s heart deserves a special mention because it produces genuine wall thickening in healthy people. A long-distance runner with a 13-millimeter septal wall is not a cardiomyopathy patient. The practical test is deconditioning: if the wall normalizes after months away from training, the heart was adapting, not failing. Mayo Clinic cardiologists have published extensively on the criteria that distinguish this remodeling from true HCM, including cavity size, diastolic function, and ECG patterns.
If you are an athlete facing an unexpected thickening finding, this is the rule-out that will most directly change whether you are treated as a patient at all.
Phenocopies must be excluded before any hypertrophy is labeled primary genetic HCM. Missing amyloidosis in an older adult or Fabry disease in a younger patient changes the entire management plan and the genetic advice given to your family.
Reading a Genetic Test Result Without Panic or False Reassurance
Genetic test reports use three buckets, and confusing them is one of the most common sources of harm in HCM care. Knowing which bucket your result falls into determines whether you screen relatives, sit tight, or seek a reanalysis.
- Pathogenic or likely pathogenic: The variant is a known, well-characterized cause of HCM. Your relatives can be tested for this exact change with high confidence.
- Variant of uncertain significance (VUS): The lab found a change in a sarcomere gene, but there is not enough evidence yet to call it disease-causing or benign. A VUS should not be used to make clinical decisions or to test relatives.
- Benign or likely benign: The variant is common in healthy people or has been shown not to affect protein function. Treat it as a non-finding.
A “negative” panel is not the same as a clean bill of health. It means none of the variants on the panel met the threshold for calling them pathogenic on the day the sample was processed. The ACMG (American College of Medical Genetics and Genomics) framework for variant interpretation evolves, and a VUS reported in 2019 may be reclassified in 2026 as either pathogenic or benign.
Genetic counseling before and after testing is not optional; it is the standard of care that protects you from acting on the wrong takeaway.
Specialist genetic counselors interpret your results in the context of family history, imaging, and the latest variant databases. Skipping that step is the single most common way families walk away with the wrong takeaway from a test.
Cascade Family Screening Is the Practical Next Step for Every Household
Cascade screening means testing the relatives of an affected person, one branch at a time, starting with the people most likely to carry the same variant. For HCM, the first ring is always the same, and you can use it as a roadmap before your next family conversation.
First-Degree Relatives Come First
- Parents: A clinical evaluation with imaging, plus targeted genetic testing if the proband (the first person in a family identified with a genetic condition) carries a known pathogenic variant. A parent with negative imaging and no variant is reassuring for their branch.
- Siblings: Same workup. If a parent is affected, each sibling has a 50 percent chance of carrying the variant. If neither parent carries it, the original case may be de novo, and siblings face near-background risk.
- Children: Genetic testing is most informative after age 10 to 12, because HCM can develop during adolescence. Clinical screening with echocardiography typically starts earlier and repeats every 1 to 3 years through young adulthood.
- Extended family: Once a parent is identified as a carrier, aunts, uncles, cousins, and grandparents on that side enter the cascade. The National Human Genome Research Institute supports this layered approach because it identifies at-risk relatives efficiently.
Imaging alone, without genetics, is a reasonable alternative for families who decline testing or lack access. A normal echocardiogram in a young adult does not rule out future disease, so repeat screening matters. A normal scan in a 60-year-old who has never shown thickening is far more reassuring, and that difference should temper how urgently you push each branch into follow-up.
How to Start the Conversation With Relatives
The hardest part of cascade screening is rarely the test itself. It is the phone call to a brother you have not spoken to in two years, or the email to a college-age child explaining that you carry a heart gene. A few practical steps help, and you can adapt them to your family’s communication style.
- Lead with the medical fact: “I was recently diagnosed with a heart condition that can run in families, and my cardiologist recommended that my siblings get screened” lands better than “I might have given you a bad gene.”
- Share the specific document: A clinical letter from your genetic counselor or the exact variant travels further than a memory of a conversation.
- Offer to help schedule: Relatives who are told what to do next are far more likely to act than relatives who are told to follow up on their own.
- Expect mixed reactions: Some family members will move fast. Others will sit on the information for months. Both responses are normal.
If cost is a concern, a genetic counselor can often direct your family to labs that cap out-of-pocket expense or to research programs that offer panel testing at no charge. The National Society of Genetic Counselors maintains a directory that helps locate specialists by state.
The Bottom Line
HCM is usually genetic but never exclusively so. Sarcomere mutations explain a clear majority of identifiable cases, yet up to half of patients test negative on current panels, and a meaningful share of those cases trace back to de novo mutations, undetected genes, or non-genetic phenocopies that must be excluded before any inheritance claim is made.
The practical path forward is straightforward: confirm the imaging, rule out mimics, pursue genetic counseling with a clinical-grade panel, and bring your first-degree relatives into a structured screening plan regardless of the test result. Each step protects both your prognosis and the people who share your genes.
FAQ
Can hypertrophic cardiomyopathy occur without a genetic mutation?
Yes. Up to half of HCM patients have no identifiable pathogenic sarcomere variant on current gene panels, and the disease can also result from non-genetic conditions such as amyloidosis, Fabry disease, or athlete’s heart that must be excluded before your diagnosis is finalized.
What percentage of HCM cases are non-genetic?
Estimates vary because definitions differ, but studies suggest that 40 to 60 percent of clinically diagnosed HCM patients have an identifiable pathogenic sarcomere variant. The remaining 40 to 60 percent include genotype-negative familial cases, de novo mutations with no prior family history, and phenocopies driven by other diseases.
Is HCM always inherited from a parent?
No. HCM can arise from a de novo mutation that neither parent carries, and it can also appear in families where no one else shows obvious disease because of incomplete penetrance (some carriers never develop measurable thickening) and variable expressivity (the same variant can cause mild or severe disease in different relatives).
Can you develop hypertrophic cardiomyopathy with no family history?
Yes. Roughly half of HCM patients have no known affected relatives, and a portion of those cases represent de novo mutations that arose spontaneously. A clean family history does not rule out heritable HCM and does not replace genetic counseling and imaging-based screening of your first-degree relatives.
What causes HCM if it is not genetic?
Non-genetic HCM can be caused by cardiac amyloidosis, Fabry disease, Danon disease, PRKAG2 glycogen storage disease, and long-term athletic remodeling. These conditions are called phenocopies because they look like sarcomeric HCM on a scan but require entirely different management and family counseling.
Should family members be screened if HCM has no known genetic cause?
Yes. Current guidelines from the American Heart Association and the European Society of Cardiology recommend clinical screening with echocardiography and ECG for all first-degree relatives of HCM patients, including those who test negative on genetic panels, because heritable causes may exist that current testing cannot yet detect.
